Market Place
Sourcing Support
Safety worries spur Novartis to suspend drug dosing in Huntington’s trial
25 Aug 2022 //
BIOPHARMADIVE
Sad news from Novartis: dosing suspended in VIBRANT-HD trial of branaplam
08 Aug 2022 //
HDBUZZ
Novartis receives USFDA Orphan Drug Designation for branaplam (LMI070)
20 Oct 2020 //
PRESS RELEASE
Novartis to pursue SMA drug branaplam in Huntington`s disease
20 Oct 2020 //
REUTERS
Novartis R&D boss says doesn`t see big opportunity in oral SMA therapy
05 Dec 2019 //
REUTERS
Genentech takes aim at Biogen and Novartis, highlighting an early +ve results
03 Oct 2018 //
ENDPTS
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.